EW Edwards Lifesciences Corp

Price (delayed)

$87.87

Market cap

$54.76B

P/E Ratio

69.19

Dividend/share

N/A

EPS

$1.27

Enterprise value

$54.43B

Sector: Healthcare
Industry: Medical Devices

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of ...

Highlights

The equity has grown by 10% year-on-year and by 10% since the previous quarter
The net income has grown by 7% from the previous quarter and by 2.6% YoY
EW's quick ratio is up by 17% since the previous quarter but it is down by 6% year-on-year
The price to earnings (P/E) is 53% higher than the 5-year quarterly average of 45.2 and 37% higher than the last 4 quarters average of 50.6
The debt has grown by 2.9% YoY

Key stats

What are the main financial stats of EW
Market
Shares outstanding
623.25M
Market cap
$54.76B
Enterprise value
$54.43B
Valuations
Price to earnings (P/E)
69.19
Price to book (P/B)
12.98
Price to sales (P/S)
12.51
EV/EBIT
60.21
EV/EBITDA
52.86
EV/Sales
12.46
Earnings
Revenue
$4.37B
EBIT
$904M
EBITDA
$1.03B
Free cash flow
$688.4M
Per share
EPS
$1.27
Free cash flow per share
$1.11
Book value per share
$6.77
Revenue per share
$7.02
TBVPS
$8.52
Balance sheet
Total assets
$6.8B
Total liabilities
$2.59B
Debt
$690.1M
Equity
$4.21B
Working capital
$2.13B
Liquidity
Debt to equity
0.16
Current ratio
3.52
Quick ratio
2.32
Net debt/EBITDA
-0.32
Margins
EBITDA margin
23.6%
Gross margin
75.5%
Net margin
18.2%
Operating margin
19.4%
Efficiency
Return on assets
12.3%
Return on equity
19.7%
Return on invested capital
23.5%
Return on capital employed
15.2%
Return on sales
20.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EW stock price

How has the Edwards Lifesciences stock price performed over time
Intraday
0.43%
1 week
-3.09%
1 month
3.19%
1 year
11.33%
YTD
-3.68%
QTD
-3.68%

Financial performance

How have Edwards Lifesciences's revenue and profit performed over time
Revenue
$4.37B
Gross profit
$3.3B
Operating income
$846.9M
Net income
$794.1M
Gross margin
75.5%
Net margin
18.2%
The operating income has grown by 7% from the previous quarter
The net income has grown by 7% from the previous quarter and by 2.6% YoY
EW's gross profit is up by 7% year-on-year
The company's operating margin rose by 6% QoQ but it fell by 3.5% YoY

Growth

What is Edwards Lifesciences's growth rate over time

Valuation

What is Edwards Lifesciences stock price valuation
P/E
69.19
P/B
12.98
P/S
12.51
EV/EBIT
60.21
EV/EBITDA
52.86
EV/Sales
12.46
The price to earnings (P/E) is 53% higher than the 5-year quarterly average of 45.2 and 37% higher than the last 4 quarters average of 50.6
The company's EPS rose by 7% QoQ and by 2.4% YoY
The stock's price to book (P/B) is 34% more than its 5-year quarterly average of 9.7 and 16% more than its last 4 quarters average of 11.2
The equity has grown by 10% year-on-year and by 10% since the previous quarter
The P/S is 42% above the 5-year quarterly average of 8.8 and 21% above the last 4 quarters average of 10.3
EW's revenue is up by 5% year-on-year

Efficiency

How efficient is Edwards Lifesciences business performance
The company's return on invested capital fell by 16% YoY
Edwards Lifesciences's return on equity has decreased by 12% YoY but it has increased by 4.2% QoQ
EW's return on assets is down by 12% year-on-year but it is up by 3.4% since the previous quarter
The company's return on sales rose by 6% QoQ but it fell by 2.4% YoY

Dividends

What is EW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EW.

Financial health

How did Edwards Lifesciences financials performed over time
The total assets is 163% greater than the total liabilities
EW's quick ratio is up by 17% since the previous quarter but it is down by 6% year-on-year
The total assets is up by 14% year-on-year and by 6% since the previous quarter
The debt is 84% less than the equity
The company's debt to equity fell by 11% QoQ and by 11% YoY
The equity has grown by 10% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.